WO2022134033A1 - Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators - Google Patents

Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators Download PDF

Info

Publication number
WO2022134033A1
WO2022134033A1 PCT/CN2020/139524 CN2020139524W WO2022134033A1 WO 2022134033 A1 WO2022134033 A1 WO 2022134033A1 CN 2020139524 W CN2020139524 W CN 2020139524W WO 2022134033 A1 WO2022134033 A1 WO 2022134033A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
formula
amount
less
reaction mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2020/139524
Other languages
English (en)
French (fr)
Inventor
Jeffrey Mark Dener
Hazel Joan HUNT
Travis Lemons
Gary Reid
Kilian GARREC
Thomas C. Stephens
Adam Daisuke GAMMACK YAMAGATA
Yunguo LU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Corcept Therapeutics Inc
Original Assignee
Corcept Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corcept Therapeutics Inc filed Critical Corcept Therapeutics Inc
Priority to PCT/CN2020/139524 priority Critical patent/WO2022134033A1/en
Priority to AU2021410756A priority patent/AU2021410756B2/en
Priority to PCT/US2021/064947 priority patent/WO2022140600A1/en
Priority to MX2023007404A priority patent/MX2023007404A/es
Priority to CN202180091897.1A priority patent/CN116867780A/zh
Priority to EP21912180.3A priority patent/EP4267577A4/en
Priority to CA3202354A priority patent/CA3202354A1/en
Priority to KR1020237024682A priority patent/KR20230124985A/ko
Priority to US17/560,048 priority patent/US12152028B2/en
Priority to JP2023538962A priority patent/JP7720914B2/ja
Priority to IL304005A priority patent/IL304005A/en
Publication of WO2022134033A1 publication Critical patent/WO2022134033A1/en
Anticipated expiration legal-status Critical
Priority to US18/920,639 priority patent/US20250145620A1/en
Priority to AU2025203341A priority patent/AU2025203341B2/en
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Definitions

  • corticosteroids There are two types of high-affinity receptors for corticosteroids; the type I (mineralocorticoid receptor, MR) and the type II (glucocorticoid receptor (GR) , or cortisol receptor, GR) .
  • the physiological glucocorticoid is cortisol (hydrocortisone) .
  • Glucocorticoids are secreted in response to ACTH (corticotropin) , which shows both circadian rhythm variation and elevations in response to stress and food. Cortisol levels are responsive within minutes to many physical and psychological stresses, including trauma, surgery, exercise, anxiety and depression.
  • Cortisol is a steroid and acts by binding to an intracellular, glucocorticoid receptor (GR) .
  • glucocorticoid receptors are present in two forms: a ligand-binding GR-alpha of 777 amino acids; and, a GR-beta isoform which lacks the 50 carboxy terminal residues. Since these include the ligand binding domain, GR-beta is unable to bind ligand, is constitutively localized in the nucleus, and is transcriptionally inactive.
  • the GR is also known as the GR-II .
  • the biologic effects of cortisol can be modulated at the GR level using receptor modulators, such as agonists, partial agonists and antagonists.
  • receptor modulators such as agonists, partial agonists and antagonists.
  • agonists e.g., agonists, partial agonists and antagonists.
  • antagonists include compositions which, by binding to GR, inhibit the ability of an agonist to effectively bind to and/or activate the GR.
  • One such known GR antagonist, mifepristone has been found to be an effective anti-glucocorticoid agent in humans (Bertagna (1984) J. Clin. Endocrinol. Metab. 59: 25) .
  • Relacorilant (CORT-125134) is another such glucocorticoid receptor modulator compound, and has been described previously in PCT Publication No. WO 2013/177559, and U.S. Patent No. 8,859,774. What is needed in the art are new methods of preparing relacorilant having lower impurity content. Surprisingly, the present invention meets these and other needs.
  • the present invention provides a method of preparing a compound of Formula I:
  • HX is an acid solvate
  • subscript n is from 1 to 4.
  • the present invention provides a method of preparing a compound of Formula I:
  • n is from 1 to 4.
  • the present invention provides a method of purifying a compound of Formula I:
  • a first mobile mixture comprising water in an amount of at least 95% (v/v) , formic acid in an amount of 0.05 to 0.2% (v/v) , and acetonitrile in an amount of 1 to 5% (v/v) ,
  • a second mobile mixture comprising water in an amount of 45 to 55% (v/v) , formic acid in an amount of 0.01 to 0.1% (v/v) , and acetonitrile in an amount of 45 to 55% (v/v) , and
  • a third mobile phase comprising water in an amount of 5 to 15% (v/v) , formic acid in an amount of 0.005 to 0.02% (v/v) , and acetonitrile in an amount of at least 85% (v/v) ,
  • the present invention provides a method of preparing a compound of Formula IIa:
  • the present invention provides a method of preparing a compound of Formula I:
  • R 1 is C 1-6 alkyl, C 1-10 haloalkyl, phenyl, or 4-methylphenyl;
  • n 1 to 4.
  • the present invention provides a method of preparing a compound of Formula IIb-2:
  • R 1 is C 1-6 alkyl, C 1-10 haloalkyl, phenyl, or 4-methylphenyl;
  • n 1 to 4.
  • the present invention provides a composition comprising:
  • one or more impurity in an amount of from 0.01 to 1% (w/w) .
  • the present invention provides a crystalline form of (R) - (1- (4-fluorophenyl) -1, 4, 5, 6, 7, 8-hexahydro-4aH-pyrazolo [3, 4-g] isoquinolin-4a-yl) (4- (trifluoromethyl) pyridin-2-yl) methanone tris-methanesulfonic acid:
  • XRPD pattern having peaks at about 18.2°, 18.3°, and 19.7° 2- ⁇ ⁇ 0.2° 2- ⁇ .
  • FIG. 1 shows the synthetic scheme for preparing (R) - (1- (4-fluorophenyl) -1, 4, 5, 6, 7, 8-hexahydro-4aH-pyrazolo [3, 4-g] isoquinolin-4a-yl) (4- (trifluoromethyl) pyridin-2-yl) methanone tris-methanesulfonic acid (relacorilant) according to Example 3.
  • FIG. 2 shows the X-ray powder diffraction (XRPD) pattern of (R) - (1- (4-fluorophenyl) -1, 4, 5, 6, 7, 8-hexahydro-4aH-pyrazolo [3, 4-g] isoquinolin-4a-yl) (4- (trifluoromethyl) pyridin-2-yl) methanone tris-methanesulfonic acid.
  • XRPD X-ray powder diffraction
  • FIG. 3 shows the differential scanning calorimetry (DSC) thermogram of (R) - (1- (4-fluorophenyl) -1, 4, 5, 6, 7, 8-hexahydro-4aH-pyrazolo [3, 4-g] isoquinolin-4a-yl) (4- (trifluoromethyl) pyridin-2-yl) methanone tris-methanesulfonic acid.
  • FIG. 4 shows the thermal gravimetric analysis of (R) - (1- (4-fluorophenyl) -1, 4, 5, 6, 7, 8-hexahydro-4aH-pyrazolo [3, 4-g] isoquinolin-4a-yl) (4- (trifluoromethyl) pyridin-2-yl) methanone tris-methanesulfonic acid.
  • FIG. 5 shows the X-ray powder diffraction (XRPD) pattern of (R) - (1- (4-fluorophenyl) -1, 4, 5, 6, 7, 8-hexahydro-4aH-pyrazolo [3, 4-g] isoquinolin-4a-yl) (4- (trifluoromethyl) pyridin-2-yl) methanone tris-oxalic acid.
  • XRPD X-ray powder diffraction
  • FIG. 6 shows the differential scanning calorimetry (DSC) thermogram of (R) - (1- (4-fluorophenyl) -1, 4, 5, 6, 7, 8-hexahydro-4aH-pyrazolo [3, 4-g] isoquinolin-4a-yl) (4- (trifluoromethyl) pyridin-2-yl) methanone tris-oxalic acid.
  • FIG. 7 shows the thermal gravimetric analysis of (R) - (1- (4-fluorophenyl) -1, 4, 5, 6, 7, 8-hexahydro-4aH-pyrazolo [3, 4-g] isoquinolin-4a-yl) (4- (trifluoromethyl) pyridin-2-yl) methanone tris-oxalic acid.
  • FIG. 8 shows the X-ray powder diffraction (XRPD) pattern of (R) - (1- (4-fluorophenyl) -1, 4, 5, 6, 7, 8-hexahydro-4aH-pyrazolo [3, 4-g] isoquinolin-4a-yl) (4- (trifluoromethyl) pyridin-2-yl) methanone tris-hydrochloric acid.
  • XRPD X-ray powder diffraction
  • FIG. 9 shows the differential scanning calorimetry (DSC) thermogram of (R) - (1- (4-fluorophenyl) -1, 4, 5, 6, 7, 8-hexahydro-4aH-pyrazolo [3, 4-g] isoquinolin-4a-yl) (4- (trifluoromethyl) pyridin-2-yl) methanone tris-hydrochloric acid.
  • FIG. 10 shows the thermal gravimetric analysis of (R) - (1- (4-fluorophenyl) -1, 4, 5, 6, 7, 8-hexahydro-4aH-pyrazolo [3, 4-g] isoquinolin-4a-yl) (4- (trifluoromethyl) pyridin-2-yl) methanone tris-hydrochloric acid.
  • the instant disclosure describes new methods of preparing the compound of Formula I, (R) - (1- (4-fluorophenyl) -6- ( (1-methyl-1H-pyrazol-4-yl) sulfonyl) -1, 4, 5, 6, 7, 8-hexahydro-4aH-pyrazolo [3, 4-g] isoquinolin-4a-yl) (4- (trifluoromethyl) pyridin-2-yl) methanone (relacorilant) , having lower impurity levels than the methods previously described.
  • Relacorilant can also be named (R) - (1- (4-fluorophenyl) -6- ( (1-methyl-1H-pyrazol-4-yl) sulfonyl) -4, 4a, 5, 6, 7, 8-hexahydro-1H -pyrazolo [3, 4-g] isoquinolin-4a-yl) (4- (trifluoromethyl) pyridin-2-yl) methanone, as in Example 18 of U.S. Patent No. 8,859,774.
  • the instant disclosure also describes compositions of relacorilant that have lower impurity levels.
  • “About” when referring to a value includes the stated value +/-10%of the stated value. For example, about 50%includes a range of from 45%to 55%, while about 20 molar equivalents includes a range of from 18 to 22 molar equivalents. Accordingly, when referring to a range, “about” refers to each of the stated values +/-10%of the stated value of each end of the range. For instance, a ratio of from about 1 to about 3 (weight/weight) includes a range of from 0.9 to 3.3.
  • Forming a reaction mixture refers to the process of bringing into contact at least two distinct species such that they mix together and can react. It should be appreciated, however, the resulting reaction product can be produced directly from a reaction between the added reagents or from an intermediate from one or more of the added reagents which can be produced in the reaction mixture.
  • Dissolve refers to a solid material that is substantially soluble in a particular solvent.
  • the solid material can be greater than 90%soluble in the solvent, or greater than 91, 92, 93, 94, 95, 96, 97, 98, or greater than 99%soluble in the solvent.
  • “Distilling” “distill” or “distillation” refers to the separation of components in a liquid mixture using a combination of temperature and pressure.
  • the target component is converted from a liquid to a gas followed by condensing the gas back to a liquid to separate the target component from the other components of the mixture.
  • “Eluting” refers to the process of separating a target component from other components in a mixture by passing the mixture over a stationary phase.
  • the target component is eluted from the stationary phase using a mobile phase that can include any suitable solvent or acid.
  • Precipitate refers to a solid formed from a solution, such as adding a first solvent in which a compound is dissolved to an excess of a second solvent in which the compound is not substantially soluble such that the dissolved compound comes out of solution and forms a solid.
  • substantially free refers to a composition having an undesired component in an amount less than 5%, less than 1%, less than 0.5%or even less than 0.1%by weight.
  • Aqueous phase refers to a mixture containing water.
  • Organic phase refers to a mixture containing water-miscible or –immiscible solvents capable of dissolving either or both of water-soluble and water-insoluble organic compounds.
  • the organic phase of the present invention can formed from one or more organic solvents.
  • Exemplary organic solvents can be non-polar aprotic solvents, polar aprotic solvents, and polar protic solvents.
  • Representative solvents include, but are not limited to, pentanes, hexanes, hexane, heptanes, benzene, toluene, diethyl ether, tetrahydrofuran, acetone, ethyl acetate, acetonitrile, methylene chloride, chloroform, etc.
  • Acid refers to a compound that is capable of donating a proton (H + ) under the Bronsted-Lowry definition, or is an electron pair acceptor under the Lewis definition.
  • Acids useful in the present invention are Bronsted-Lowry acids that include, but are not limited to, alkanoic acids or carboxylic acids (formic acid, acetic acid, citric acid, lactic acid, oxalic acid, etc. ) , sulfonic acids and mineral acids, as defined herein.
  • Mineral acids are inorganic acids such as hydrogen halides (hydrofluoric acid, hydrochloric acid, hydrobromice acid, etc.
  • Sulfonic acids include methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, triflouromethanesulfonic acid, camphorsulfonic acid, among others.
  • Grignard reagent refers to a reagent containing a complex of magnesium metal, a halide, and an alkyl ligand, capable of forming a carbon-carbon bond.
  • Representative Grignard reagents include, but are not limited to, iPrMgCl and iPrMgBr.
  • Non-nucleophilic base refers to a base that is a moderate to strong base but at the same time is a poor nucleophile.
  • Representative non-nucleophilic bases include bases such as potassium carbonate, sodium carbonate, potassium tert-butoxide, and sodium tert-butoxide, as well as amine bases, such as triethylamine, diisopropylethyl amine, N, N-diethylaniline, pyridine, 2, 6-lutidine, 2, 4, 6-collidine, 4-dimethylaminopyridine, and quinuclidine. This includes non-nucleophilic amine bases.
  • Solvent refers to a substance, such as a liquid, capable of dissolving a solute.
  • Solvents can be polar or non-polar, protic or aprotic.
  • Polar solvents typically have a dielectric constant greater than about 5 or a dipole moment above about 1.0, and non-polar solvents have a dielectric constant below about 5 or a dipole moment below about 1.0.
  • Protic solvents are characterized by having a proton available for removal, such as by having a hydroxy or carboxy group. Aprotic solvents lack such a group.
  • Representative polar protic solvents include alcohols (methanol, ethanol, propanol, isopropanol, etc. ) , acids (formic acid, acetic acid, etc. ) and water.
  • Representative polar aprotic solvents include dichloromethane, chloroform, tetrahydrofuran, diethyl ether, 1, 4-dioxane, acetone, ethyl acetate, dimethylformamide, dimethylacetamide, acetonitrile and dimethyl sulfoxide.
  • Representative non-polar solvents include alkanes (pentanes, hexanes, etc. ) , cycloalkanes (cyclopentane, cyclohexane, etc. ) , benzene, and toluene. Other solvents are useful in the present invention.
  • Root temperature is the range of air temperatures generally considered to be suitable for human occupancy, or between about 15 degrees Celsius (59 degrees Fahrenheit) and 25 degrees Celsius (77 degrees Fahrenheit) .
  • Vacuum or “reduced pressure” refers to a pressure that is less than atmospheric pressure. Atmospheric pressure is measured as about 1013 mbar, 760 mm Hg, or about 14.7 psi. Accordingly, vacuum can be less than 1013 mbar, or less than 100, 10, 1, 0.1, or less than 0.01 mbar.
  • Alkyl refers to a straight or branched, saturated, aliphatic radical having the number of carbon atoms indicated. Alkyl can include any number of carbons, such as C 1-2 , C 1-3 , C 1-4 , C 1-5 , C 1-6 , C 1-7 , C 1-8 , C 1-9 , C 1-10 , C 2-3 , C 2-4 , C 2-5 , C 2-6 , C 3-4 , C 3-5 , C 3-6 , C 4-5 , C 4-6 and C 5-6 .
  • C 1-6 alkyl includes, but is not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, hexyl, etc.
  • Alkyl can also refer to alkyl groups having up to 20 carbons atoms, such as, but not limited to heptyl, octyl, nonyl, decyl, etc. Alkyl groups can be substituted or unsubstituted.
  • Halogen refers to fluorine, chlorine, bromine and iodine.
  • Haloalkyl refers to alkyl, as defined above, where some or all of the hydrogen atoms are replaced with halogen atoms.
  • alkyl groups can have any suitable number of carbon atoms, such as C 1-6 .
  • haloalkyl includes trifluoromethyl, fluoromethyl, etc.
  • perfluoro can be used to define a compound or radical where all the hydrogens are replaced with fluorine.
  • perfluoromethyl refers to 1, 1, 1-trifluoromethyl.
  • “Pharmaceutically acceptable salt” refers to acid or base salts of the compounds used in the methods of the present invention.
  • Illustrative examples of pharmaceutically acceptable salts are mineral acid (hydrochloric acid, hydrobromic acid, phosphoric acid, and the like) salts, organic acid (acetic acid, propionic acid, glutamic acid, citric acid and the like) salts, quaternary ammonium (methyl iodide, ethyl iodide, and the like) salts. It is understood that the pharmaceutically acceptable salts are non-toxic. Additional information on suitable pharmaceutically acceptable salts can be found in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., 1985, which is incorporated herein by reference.
  • composition as used herein is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product, which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.
  • pharmaceutically acceptable it is meant the carrier (s) , diluent (s) or excipient (s) must be compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
  • “Pharmaceutically acceptable excipient” refers to a substance that aids the administration of an active agent to and absorption by a subject.
  • Pharmaceutical excipients useful in the present invention include, but are not limited to, binders, fillers, disintegrants, lubricants, surfactants, coatings, sweeteners, flavors and colors.
  • binders include, but are not limited to, binders, fillers, disintegrants, lubricants, surfactants, coatings, sweeteners, flavors and colors.
  • Treating” , “treating” and “treatment” refer to any indicia of success in the treatment or amelioration of an injury, pathology or condition, including any objective or subjective parameter such as abatement; remission; diminishing of symptoms or making the injury, pathology or condition more tolerable to the patient; slowing in the rate of degeneration or decline; making the final point of degeneration less debilitating; improving a patient's physical or mental well-being.
  • the treatment or amelioration of symptoms can be based on objective or subjective parameters; including the results of a physical examination, neuropsychiatric exams, and/or a psychiatric evaluation.
  • administering refers to oral administration, administration as a suppository, topical contact, parenteral, intravenous, intraperitoneal, intramuscular, intralesional, intranasal or subcutaneous administration, intrathecal administration, or the implantation of a slow-release device e.g., a mini-osmotic pump, to the subject.
  • a slow-release device e.g., a mini-osmotic pump
  • “Patient” or “subject” refers to a living organism suffering from or prone to a disease or condition that can be treated by administration of a pharmaceutical composition as provided herein.
  • Non-limiting examples include humans, other mammals, bovines, rats, mice, dogs, monkeys, goat, sheep, cows, deer, horse, and other non-mammalian animals.
  • the patient is human.
  • “Therapeutically effective amount” refers to an amount of a compound or of a pharmaceutical composition useful for treating or ameliorating an identified disease or condition, or for exhibiting a detectable therapeutic or inhibitory effect. The exact amounts will depend on the purpose of the treatment, and will be ascertainable by one skilled in the art using known techniques (see, e.g., Lieberman, Pharmaceutical Dosage Forms (vols. 1-3, 1992) ; Lloyd, The Art, Science and Technology of Pharmaceutical Compounding (1999) ; Pickar, Dosage Calculations (1999) ; and Remington: The Science and Practice of Pharmacy, 20th Edition, 2003, Gennaro, Ed., Lippincott, Williams & Wilkins) .
  • Glucocorticoid receptor refers to one of the family of intracellular receptors which specifically bind to cortisol and/or cortisol analogs such as dexamethasone (See, e.g., Turner & Muller, J. Mol. Endocrinol. October 1, 2005 35 283-292) .
  • the glucocorticoid receptor is also referred to as the cortisol receptor.
  • the term includes isoforms of GR, recombinant GR and mutated GR.
  • a cortisol receptor is a glucocorticoid receptor (GR) , specifically the type II GR, which specifically binds cortisol and/or cortisol analogs such as dexamethasone (See, e.g., Turner & Muller, J. Mol. Endocrinol. October 1, 2005 35 283-292) .
  • GR glucocorticoid receptor
  • MR Mineralocorticoid receptor
  • GR I glucocorticoid receptor
  • Glucocorticoid receptor modulator refers to any compound which modulates any biological response associated with the binding of a glucocorticoid receptor to an agonist.
  • the glucocorticoid receptor may be GR, or both.
  • a GRM that acts as an agonist such as dexamethasone, increases the activity of tyrosine aminotransferase (TAT) in HepG2 cells (ahuman liver hepatocellular carcinoma cell line; ECACC, UK) .
  • TAT tyrosine aminotransferase
  • TAT activity can be measured as outlined in the literature by A. Ali et al., J. Med. Chem., 2004, 47, 2441-2452.
  • Glucocorticoid receptor antagonist refers to any compound which inhibits any biological response associated with the binding of a glucocorticoid receptor to an agonist.
  • the glucocorticoid receptor may be GR, or both.
  • GR antagonists can be identified by measuring the ability of a compound to inhibit the effect of dexamethasone. TAT activity can be measured as outlined in the literature by A. Ali et al., J. Med. Chem., 2004, 47, 2441-2452.
  • An inhibitor is a compound with an IC 50 (half maximal inhibition concentration) of less than 10 micromolar. See Example 1 of U.S. Patent 8,685,973, the entire contents of which is hereby incorporated by reference in its entirety.
  • Modulate and modulating are used in accordance with its plain ordinary meaning and refer to the act of changing or varying one or more properties. “Modulation” refers to the process of changing or varying one or more properties. For example, as applied to the effects of a modulator on a target protein, to modulate means to change by increasing or decreasing a property or function of the target molecule or the amount of the target molecule.
  • Modulator refers to a composition that increases or decreases the level of a target molecule or the function of a target molecule or the physical state of the target of the molecule.
  • Antagonizing refers to inhibiting the binding of an agonist at a receptor molecule or to inhibiting the signal produced by a receptor-agonist.
  • a receptor antagonist inhibits or dampens agonist-mediated responses, such as gene expression.
  • Antagonist refers to a substance capable of detectably lowering expression or activity of a given gene or protein.
  • the antagonist can inhibit expression or activity 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%or less in comparison to a control in the absence of the antagonist. In some embodiments, the inhibition is 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, or more than the expression or activity in the absence of the antagonist.
  • “Inhibition” refers to a compound that prohibits or a method of prohibiting, a specific action or function.
  • disorders or conditions refers to a state of being or health status of a patient or subject capable of being treated with the glucocorticoid receptor modulator of the present invention.
  • disorders or conditions include, but are not limited to, fatty liver disease, nonalcoholic fatty liver disease (NAFLD) , nonalcoholic steatohepatitis (NASH) , and antipsychotic-induced weight gain.
  • NAFLD nonalcoholic fatty liver disease
  • NASH nonalcoholic steatohepatitis
  • antipsychotic-induced weight gain antipsychotic-induced weight gain.
  • Fatty liver disease refers to a disease or a pathological condition caused by, at least in part, abnormal hepatic lipid deposits.
  • Fatty liver disease includes, e.g., alcoholic fatty liver disease, nonalcoholic fatty liver disease, and acute fatty liver of pregnancy.
  • Fatty liver disease may be, e.g., macrovesicular steatosis or microvesicular steatosis.
  • Non-alcoholic fatty liver disease refers to one of the types of fatty liver disease which occurs when fat is deposited (steatosis) in the liver due to causes other than excessive alcohol use. NAFLD is considered to cover a spectrum of disease activity. This spectrum begins as fatty accumulation in the liver (hepatic steatosis) . Most people with NAFLD have few or no symptoms. Patients may complain of fatigue, malaise, and dull right-upper-quadrant abdominal discomfort. Mild jaundice may be noticed, although this is rare. More commonly NAFLD is diagnosed following abnormal liver function tests during routine blood tests. By definition, alcohol consumption of over 20 g/day (about 25 ml/day of net ethanol) excludes the condition.
  • Non-alcoholic steatohepatitis refers to the most extreme form of NAFLD. NAFLD can progress to become non-alcoholic steatohepatitis (NASH) , a state in which steatosis is combined with inflammation and fibrosis (steatohepatitis) . NASH is a progressive disease. Over a 10-year period, up to 20%of patients with NASH will develop cirrhosis of the liver, and 10%will suffer death related to liver disease.
  • NASH non-alcoholic steatohepatitis
  • “Substance use disorder” refers to the compulsive use of a substance despite unpleasant or harmful consequences of that use.
  • a substance use disorder may involve impaired control (e.g., use of excessive amounts of the substance, or over longer periods of time, than was originally intended) , social impairment (e.g., failure to fulfill major roles obligations at work, school, or home) , risky use (e.g., recurrent use of the substance in situations in which it is physically hazardous) , and pharmacological criteria (e.g., tolerance or withdrawal) .
  • a substance use disorder may have formerly been termed an “addiction” although, since the publication of the Diagnostic and Statistical Manual of Mental Disorders Fifth Edition DSM-5 (hereafter “DSM-V” ) , terms such as “addiction” and “addict” have been replaced for the terms “substance use disorder” (replacing “addiction” ) and person suffering from a substance use disorder (replacing “addict” ) .
  • a person suffering from a substance use disorder may be termed as suffering from a substance use disorder related to a particular substance; prior to the publication of DSM-V, such a person may have been described as being “addicted to” that substance. For example, where a person has a substance use disorder related to a stimulant, that person may have been described as being “addicted to” that stimulant prior to the publication of DSM-V.
  • “Substance” as recited in phrases such as “substance use disorder related to said substance” and “substance use disorder related to the substance” refers to the substance for which a patient has a craving, or which the patient uses compulsively despite unpleasant or harmful consequences of that use.
  • a “substance” is the substance used by, or ingested, or otherwise administered to (including self-administration) a person who suffers from a substance use disorder related to that substance.
  • the terms “substance of addiction” , and “substance of abuse” may have formerly been used to refer such a substance, which substance may formerly have been termed an “addictive substance” (e.g., prior to the publication of DSM-V) .
  • “Person suffering from a substance use disorder” refers to a person suffering from a substance use disorder related to a particular substance, or, in some cases, more than one particular substance.
  • a “substance” may be a drug, or alcohol, or a cigarette, or other substance a person may take (ingest) .
  • a “substance” may be alcohol, a stimulant, an opioid, or other substance.
  • the present invention provides methods for preparing the compound of Formula I, (R) - (1- (4-fluorophenyl) -6- ( (1-methyl-1H-pyrazol-4-yl) sulfonyl) -1, 4, 5, 6, 7, 8-hexahydro-4aH-pyrazolo [3, 4-g] isoquinolin-4a-yl) (4- (trifluoromethyl) pyridin-2-yl) methanone (relacorilant) :
  • the present invention provides a method of preparing a compound of Formula I:
  • HX is an acid solvate
  • subscript n is from 1 to 4.
  • HX is HCl, HBr,
  • R 1 is C 1-6 alkyl, C 1-10 haloalkyl, phenyl, or 4-methylphenyl.
  • the compound of Formula IIb can have the structure:
  • n is from 1 to 4.
  • the compound of Formula IIb can have the structure:
  • n is from 1 to 4.
  • the compound of Formula IIb can have the structure:
  • R 1 is C 1-6 alkyl, C 1-10 haloalkyl, phenyl, or 4-methylphenyl; and subscript n is from 1 to 4.
  • the compound of Formula IIb can have the structure:
  • n is from 1 to 4.
  • the compound of Formula IIb can have the structure:
  • R 1 is C 1-6 alkyl, C 1-10 haloalkyl, phenyl, or 4-methylphenyl; and subscript n is from 1 to 4.
  • the compound of Formula IIb can have the structure:
  • R 1 is C 1-6 alkyl, C 1-10 haloalkyl, phenyl, or 4-methylphenyl; and subscript n is from 1 to 4.
  • HX is HBr.
  • the compound of Formula I can be prepared from the compound of Formula IIb-1:
  • the present invention provides a method of preparing a compound of Formula I:
  • n is from 1 to 4.
  • Subscript n can be 1, 1.5, 2, 2.5, 3, 3.5 or 4. In some embodiments, subscript n is 1. In some embodiments, subscript n is 2. In some embodiments, subscript n is 3. In some embodiments, subscript n is 4. In some embodiments, the compound of Formula IIb-1 has the structure:
  • the first reaction mixture further comprises a non-nucleophilic amine base.
  • Any suitable non-nucleophilic amine base can be used in the first reaction mixture.
  • the non-nucleophilic amine base comprises trimethylamine, triethylamine, N, N-diisopropyl ethylamine (DIPEA) , N, N-dimethyl isopropylamine (DIMPA) , 1-ethylpiperidine, N-methylmorpholine, N-methylpyrrolidine, pyridine, N, N-dimethylaniline, ⁇ , ⁇ -diethylaniline, 2, 6-lutidine, 2, 4, 6-collidine, 4-dimethyl aminopyridine (DMAP) , quinuclidine, 4-pyrrolidinopyridine, 1, 4-diazabicyclo [2.2.2] octane (DABCO) , or mixtures thereof.
  • the non-nucleophilic amine base comprises trimethylamine, trie
  • the first reaction mixture can include any suitable solvent.
  • the solvent can be an organic solvent including, but not limited to, ethyl acetate, isopropylacetate, and n-butyl acetate.
  • the first reaction mixture further comprises a first solvent.
  • the first solvent includes ethyl acetate, isopropyl acetate, or n-butyl acetate.
  • the first reaction mixture further comprises isopropyl acetate.
  • the sulfonyl chloride used in the first reaction mixture can be present in any suitable molar ratio to the compound of Formula IIb-1.
  • the sulfonyl chloride can be present in a molar ratio of from 1.0 to 3.0 to the compound of Formula IIb-1, from 1.0 to 2.5, from 1.0 to 2.0, from 1.0 to 1.5, from 1.1 to 2.4, or from 1.2 to 2.3 to the compound of Formula IIb-1.
  • the sulfonyl chloride is present in a molar ratio of 1.2 to 2.3 to the compound of Formula IIb-1.
  • the sulfonyl chloride can be gpresent in a molar ratio of 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2 or 2.3 to the compound of Formula IIb-1. In some embodiments, the sulfonyl chloride can be present in a molar ratio of about 1.2 to the compound of Formula IIb-1.
  • the compound of Formula I can be prepared in any suitable yield.
  • the compound of Formula I can be prepared in a yield of at least 10, 20, 30, 40, 50, 60, 65, 70, 75, 80, 85, 90, or at least 95%.
  • the compound of Formula I can be prepared in a yield of at least 60%.
  • the compound of Formula I can be prepared in any suitable purity.
  • the compound of Formula I can be prepared in a purity of at least 90%, or 91, 92, 93, 94, 95, 96, 97, 98, or at least 99%.
  • the compound of Formula I can be prepared in a purity of at least 96%.
  • the compound of Formula I can be prepared in a purity of at least 97%.
  • the compound of Formula I can be prepared in a purity of at least 98%.
  • the compound of Formula I can be prepared in a purity of at least 99%.
  • the compound of Formula I can be prepared with any acceptable amount of a compound of Formula X-4:
  • the compound Formula I can be prepared containing less than 5% (w/w) , or 4, 3, 2, 1, 0.9, 0.8, 0.75, 0.7, 0.6, 0.5, 0.4, 0.3, 0.25, 0.2, or less than 0.1% (w/w) of the compound of Formula X-4.
  • the compound of Formula I can be prepared containing less than 0.5% (w/w) of the compound of Formula X-4.
  • the compound of Formula I can be prepared containing less than 0.3% (w/w) of the compound of Formula X-4.
  • the compound of Formula I can be prepared containing less than 0.1% (w/w) of the compound of Formula X-4.
  • the compound of Formula I can be prepared with any acceptable amount of Formula X-5.
  • the compound Formula I can be prepared containing less than 5% (w/w) , or 4, 3, 2, 1, 0.9, 0.8, 0.75, 0.7, 0.6, 0.5, 0.4, 0.3, 0.25, 0.2, or less than 0.1% (w/w) of the compound of Formula X-5.
  • the compound of Formula I can be prepared containing less than 1% (w/w) of the compound of Formula X-5.
  • the compound of Formula I can be prepared containing less than 0.75% (w/w) of the compound of Formula X-5.
  • the compound of Formula I can be prepared containing less than 0.5% (w/w) of the compound of Formula X-5. In some embodiments, the compound of Formula I can be prepared containing less than 0.2% (w/w) of the compound of Formula X-5.
  • the compound of Formula I can be prepared with any acceptable amount of a compound of Formula X-6:
  • the compound Formula I can be prepared containing less than 5% (w/w) , or 4, 3, 2, 1, 0.9, 0.8, 0.75, 0.7, 0.6, 0.5, 0.4, 0.3, 0.25, 0.2, or less than 0.1% (w/w) of the compound of Formula X-6.
  • the compound of Formula I can be prepared containing less than 0.25% (w/w) of the compound of Formula X-6.
  • the compound of Formula I can be prepared containing less than 0.2% (w/w) of the compound of Formula X-6.
  • the compound of Formula I can be prepared containing less than 0.1% (w/w) of the compound of Formula X-6.
  • the compound of Formula I can be prepared with 1, 4-diboromopentane in an amount of less than 10 ppm.
  • the compound of Formula I can be prepared with an amount of 1, 4-dibromopentane in an amount of less than 10 ppm, or less than 10, 9, 8, 7, 6, 5, or less than 4 ppm.
  • the compound of Formula I can be prepared with an amount of 1, 4-dibromopentane in an amount of less than 8 ppm.
  • the compound of Formula I can be prepared with an amount of 1, 4-dibromopentane in an amount of less than 6 ppm.
  • the compound of Formula I can be prepared with an amount of 1, 4-dibromopentane in an amount of less than 4 ppm.
  • the compound of Formula I can be prepared with methyl-1-methyl-1H-pyrazole-4-sulfonate:
  • the compound of Formula I can be prepared with an amount of methyl-1-methyl-1H-pyrazole-4-sulfonate in an amount of less than 10 ppm, or less than 10, 9, 8, 7, 6, 5, or less than 4 ppm. In some embodiments, the compound of Formula I can be prepared with an amount of methyl-1-methyl-1H-pyrazole-4-sulfonate in an amount of less than 8 ppm. In some embodiments, the compound of Formula I can be prepared with an amount of methyl-1-methyl-1H-pyrazole-4-sulfonate in an amount of less than 6 ppm. In some embodiments, the compound of Formula I can be prepared with an amount of methyl-1-methyl-1H-pyrazole-4-sulfonate in an amount of less than 4 ppm.
  • the compound of Formula I can be prepared with 1-methyl-1H-pyrazole-4-sulfonyl chloride:
  • the compound of Formula I can be prepared with an amount of 1-methyl-1H-pyrazole-4-sulfonyl chloride in an amount of less than 10 ppm, or less than 10, 9, 8, 7, 6, 5, or less than 4 ppm. In some embodiments, the compound of Formula I can be prepared with an amount of 1-methyl-1H-pyrazole-4-sulfonyl chloride in an amount of less than 8 ppm. In some embodiments, the compound of Formula I can be prepared with an amount of 1-methyl-1H-pyrazole-4-sulfonyl chloride in an amount of less than 6 ppm. In some embodiments, the compound of Formula I can be prepared with an amount of 1-methyl-1H-pyrazole-4-sulfonyl chloride in an amount of less than 4 ppm.
  • the method of preparing the compound of Formula I includes:
  • the method of preparing the compound of Formula I also includes after step (a) :
  • the organic phase can include any suitable organic solvent.
  • the first organic phase includes the first solvent.
  • silica gel can be used in the method of the present invention.
  • Representative silica gel include, but are not limited to, 200-300 mesh silica gel, or 60-80 mesh, 80-120 mesh, 100-200 mesh, etc. In some embodiments, the silica gel is 200-300 mesh silica gel.
  • the compound of Formula IIb-1 can be prepared by a variety of methods.
  • the compound of Formula IIb-1 is prepared by the step of:
  • the gaseous HBr can be present in any suitable partial pressure.
  • the second reaction mixture can also include a second solvent.
  • the second solvent can be any suitable solvent including, but not limited to, tetrahydrofuran, 2-methyltetrahydrofuran, toluene or xylene.
  • the second reaction mixture further comprises a second solvent.
  • the second solvent can be tetrahydrofuran, 2-methyltetrahydrofuran, toluene or xylene.
  • the second reaction mixture further comprises toluene.
  • the compound of Formula I can be prepared from the compound of Formula IIa.
  • the compound of Formula IIa corresponds to Intermediate 29 of U.S. Patent No. 8,859,974, (R) -tert-butyl 1- (4-chlorophenyl) -4a- (4- (trifluoromethyl) picolinoyl) -4a, 5, 7, 8-tetrahydro-1H-pyrazolo [3, 4-g] isoquinoline-6 (4H) -carboxylate.
  • the compound of Formula IIa can also be named tert-butyl (R) -1- (4-fluorophenyl) -4a- (4- (trifluoromethyl) picolinoyl) -1, 4, 4a, 5, 7, 8-hexahydro-6H-pyrazolo [3, 4-g] isoquinoline-6-carboxylate.
  • the compound of Formula I is prepared by the steps of:
  • the compound of Formula IIa can be prepared by any suitable method.
  • the compound of Formula IIa is prepared by:
  • the method of preparing the compound of Formula I comprises:
  • the method of preparing the compound of Formula I comprises following step (a) :
  • the compound of Formula I can be purified by a variety of methods.
  • the present invention provides a method of purifying a compound of Formula I:
  • a first mobile mixture comprising water in an amount of at least 95% (v/v) , formic acid in an amount of 0.05 to 0.2% (v/v) , and acetonitrile in an amount of 1 to 5% (v/v) ,
  • a second mobile mixture comprising water in an amount of 45 to 55% (v/v) , formic acid in an amount of 0.01 to 0.1% (v/v) , and acetonitrile in an amount of 45 to 55% (v/v) , and
  • a third mobile phase comprising water in an amount of 5 to 15% (v/v) , formic acid in an amount of 0.005 to 0.02% (v/v) , and acetonitrile in an amount of at least 85% (v/v) ,
  • the filter can be a cartridge filter.
  • the filter can be a CUNO cartridge filter.
  • the purified compound of Formula I has a purity of at least 99%, and comprises 1, 4-dibromopentane in an amount of less than 8 ppm.
  • the purified compound of Formula I has a purity of at least 99%, and comprises
  • the compound of Formula I purified by the method above can be prepared by the methods described above.
  • the compound of Formula IIa can be prepared by any suitable method.
  • the present invention provides a method of preparing a compound of Formula IIa:
  • the Grignard reagent can be any suitable Grignard reagent.
  • the Grignard reagent comprises iPrMgCl or iPrMgBr. In some embodiments, the Grignard reagent comprises iPrMgBr.
  • the Grignard reagent can be present in any suitable molar ratio to the compound of Formula III.
  • the Grignard reagent can be present in a molar ratio of from 1.0 to 2.0, or from 1.1 to 1.9, from 1.2 to 1.8, from 1.3 to 1.8, from 1.4 to 1.7, from 1.5 to 1.7, or from 1.6 to 1.7 to the compound of Formula III.
  • the Grignard reagent can be present in a molar ratio of from 1.5 to 1.7 to the compound of Formula III.
  • the Grignard reagent can be present in a molar ratio of about 1.5, or about 1.55, 1.60, 1.65, 1.70, or about 1.75 to the compound of Formula III.
  • the Grignard reagent can be present in a molar ratio of about 1.65 to the compound of Formula III.
  • the pyridine can be present in any suitable ratio to the compound of Formula III.
  • the pyridine can be present in a molar ratio of 1.0 to 2.0, or from 1.0 to 1.9, from 1.0 to 1.8, from 1.0 to 1.7, from 1.0 to 1.6, from 1.0 to 1.5, from 1.1 to 1.5, from 1.2 to 1.5, or from 1.3 to 1.5 to the compound of Formula III.
  • the pyridine can be present in a molar ratio of from 1.0 to 1.5 to the compound of Formula III.
  • the pyridine can be present in a molar ratio of about 1.0, or about 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9 or about 2.0 to the compound of Formula III.
  • the pyridine can be present in a molar ratio of about 1.4 to the compound of Formula III.
  • the third reaction mixture can also include a third solvent.
  • the third solvent can be any suitable solvent including, but not limited to, tetrahydrofuran, 2-methyltetrahydrofuran, toluene xylene, or combinations thereof.
  • the third reaction mixture further comprises a third solvent.
  • the third solvent can be tetrahydrofuran, 2-methyltetrahydrofuran, toluene, xylene, or combinations thereof.
  • the third reaction mixture further comprises 2-methyltetrahydrofuran and toluene.
  • the method of preparing the compound of Formula IIa also includes: (c1) adding an acid and water to the third reaction mixture to form a workup mixture; and (c2) distilling the workup mixture to form an intermediate mixture comprising the compound of Formula IIa, 2-methyltetrahydrofuran in an amount of less than 200 ppm, and water in an amount of less than 0.5% (w/w) .
  • the acid of step (c1) can be any suitable acid.
  • the acid comprises formic acid, acetic acid, propanoic acid, butyric acid, hexanoic acid, octanoic acid, trifluoroacetic acid, or mixtures thereof.
  • the acid comprises acetic acid.
  • the intermediate mixture can include 2-methyltetrahydrofuran in any amount of less than 200 ppm.
  • the intermediate mixture can include 2-methyltetrahydrofuran in an amount of less than 200 ppm, or less than 190, 180, 170, 160, 150, 140, 130, 120, 110, 100, 90, 80, 70, 60, or less than 50 ppm.
  • the intermediate mixture can include 2-methyltetrahydrofuran in an amount of less than 100 ppm.
  • the method of preparing the compound of Formula IIa comprises:
  • HX is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • R 1 is C 1-6 alkyl, C 1-10 haloalkyl, phenyl, or 4-methylphenyl;
  • n 1 to 4.
  • the compound of Formula I can be prepared from the compound of Formula IIb-2:
  • the present invention provides a method of preparing a compound of Formula I:
  • R 1 is C 1-6 alkyl, C 1-10 haloalkyl, phenyl, or 4-methylphenyl;
  • n 1 to 4.
  • R 1 is C 1-2 alkyl, C 1-2 haloalkyl, phenyl, or 4-methylphenyl. In some embodiments, R 1 is methyl, ethyl, -CF 3 , phenyl, or 4-methylphenyl. In some embodiments, R 1 is methyl.
  • Subscript n can be 1, 2, 3 or 4. In some embodiments, subscript n is 1. In some embodiments, subscript n is 2. In some embodiments, subscript n is 3. In some embodiments, subscript n is 4. In some embodiments, the compound of Formula IIb-2 has the structure:
  • the fourth reaction mixture further comprises a non-nucleophilic amine base.
  • Any suitable non-nucleophilic amine base can be used in the fourth reaction mixture.
  • the non-nucleophilic amine base comprises trimethylamine, triethylamine, N, N-diisopropyl ethylamine (DIPEA) , N, N-dimethyl isopropylamine (DIMPA) , 1-ethylpiperidine, N-methylmorpholine, N-methylpyrrolidine, pyridine, N, N-dimethylaniline, ⁇ , ⁇ -diethylaniline, 2, 6-lutidine, 2, 4, 6-collidine, 4-dimethyl aminopyridine (DMAP) , quinuclidine, 4-pyrrolidinopyridine, 1, 4-diazabicyclo [2.2.2] octane (DABCO) , or mixtures thereof.
  • the non-nucleophilic amine base comprises trimethylamine, trie
  • the fourth reaction mixture can include any suitable solvent.
  • the solvent can be an organic solvent including, but not limited to, ethyl acetate, isopropylacetate, and n-butyl acetate.
  • the fourth reaction mixture further comprises a fourth solvent.
  • the fourth solvent includes ethyl acetate, isopropyl acetate, n-butyl acetate, or mixtures thereof.
  • the fourth reaction mixture further comprises ethyl acetate.
  • the sulfonyl chloride used in the fourth reaction mixture can be present in any suitable molar ratio to the compound of Formula IIb-2.
  • the sulfonyl chloride can be present in a molar ratio of from 0.5 to 2.0 to the compound of Formula IIb-2, from 0.5 to 1.5, from 0.6 to 1.4, from 0.7 to 1.3, from 0.8 to 1.2, or from 0.9 to 1.1 to the compound of Formula IIb-2.
  • the sulfonyl chloride is present in a molar ratio of 0.5 to 1.5 to the compound of Formula IIb-2.
  • the sulfonyl chloride can be present in a molar ratio of 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4 or 1.5 to the compound of Formula IIb-2. In some embodiments, the sulfonyl chloride can be present in a molar ratio of about 1.0 to the compound of Formula IIb-2.
  • the compound of Formula I can be prepared in any suitable yield.
  • the compound of Formula I can be prepared in a yield of at least 10, 20, 30, 40, 50, 60, 65, 70, 75, 80, 85, 90, or at least 95%.
  • the compound of Formula I can be prepared in a yield of at least 75%.
  • the compound of Formula I can be prepared in any suitable purity.
  • the compound of Formula I can be prepared in a purity of at least 90%, or 91, 92, 93, 94, 95, 96, 97, 98, or at least 99%.
  • the compound of Formula I can be prepared in a purity of at least 96%.
  • the compound of Formula I can be prepared in a purity of at least 97%.
  • the compound of Formula I can be prepared in a purity of at least 98%.
  • the compound of Formula I can be prepared in a purity of at least 99%.
  • the method of preparing the compound of Formula I further comprises the steps of:
  • the method of preparing the compound of Formula I from the compound of Formula IIb-2 comprises the steps of:
  • the compound of Formula I can be prepared with any acceptable amount of Formula X-5:
  • the compound Formula I can be prepared containing less than 5% (w/w) , or 4, 3, 2, 1, 0.9, 0.8, 0.75, 0.7, 0.6, 0.5, 0.4, 0.3, 0.25, 0.2, or less than 0.1% (w/w) of the compound of Formula X-5.
  • the compound of Formula I can be prepared containing less than 1% (w/w) of the compound of Formula X-5:
  • the compound of Formula I can be prepared containing less than 0.75% (w/w) of the compound of Formula X-5. In some embodiments, the compound of Formula I can be prepared containing less than 0.5% (w/w) of the compound of Formula X-5. In some embodiments, the compound of Formula I can be prepared containing less than 0.2% (w/w) of the compound of Formula X-5.
  • the compound of Formula IIb-2 can be prepared from the compound of Formula IIa.
  • the present invention provides a method of preparing a compound of Formula IIb-2:
  • R 1 is C 1-6 alkyl, C 1-10 haloalkyl, phenyl, or 4-methylphenyl;
  • n 1 to 4.
  • Subscript n can be 1, 2, 3 or 4. In some embodiments, subscript n is 1. In some embodiments, subscript n is 2. In some embodiments, subscript n is 3. In some embodiments, subscript n is 4. In some embodiments, the compound of Formula IIb-2 has the structure:
  • the fifth reaction mixture can include any suitable solvent.
  • the fifth reaction mixture includes a fifth solvent.
  • the fifth solvent can include, but is not limited to, pentanes, hexanes, heptanes, benzene, toluene, diethyl ether, tetrahydrofuran, acetone, ethyl acetate, acetonitrile, methylene chloride, and chloroform.
  • the fifth solvent includes acetonitrile, tetrahydrofuran, 2-methyltetrahydrofuran, dimethylsulfoxide (DMSO) , dimethylformamide (DMF) , methanol, ethanol, diethyl ether, methyl-t-butyl ether (MTBE) , toluene, or combinations thereof.
  • the fifth reaction mixture includes acetonitrile.
  • the compound of Formula IIa can be prepared by a variety of methods. In some embodiments, the compound of Formula IIa can be prepared by the steps of:
  • the Grignard reagent can be any suitable Grignard reagent.
  • the Grignard reagent comprises iPrMgCl or iPrMgBr. In some embodiments, the Grignard reagent comprises iPrMgCl.
  • the Grignard reagent can be present in any suitable molar ratio to the compound of Formula III.
  • the Grignard reagent can be present in a molar ratio of from 1.0 to 2.0, or from 1.1 to 1.9, from 1.2 to 1.8, from 1.3 to 1.8, from 1.4 to 1.7, from 1.5 to 1.7, or from 1.6 to 1.7 to the compound of Formula III.
  • the Grignard reagent can be present in a molar ratio of from 1.5 to 1.7 to the compound of Formula III.
  • the Grignard reagent can be present in a molar ratio of about 1.5, or about 1.55, 1.60, 1.65, 1.70, or about 1.75 to the compound of Formula III.
  • the Grignard reagent can be present in a molar ratio of about 1.65 to the compound of Formula III.
  • the pyridine can be present in any suitable ratio to the compound of Formula III.
  • the pyridine can be present in a molar ratio of 1.0 to 2.0, or from 1.0 to 1.9, from 1.0 to 1.8, from 1.0 to 1.7, from 1.0 to 1.6, from 1.0 to 1.5, from 1.1 to 1.5, from 1.2 to 1.5, or from 1.3 to 1.5 to the compound of Formula III.
  • the pyridine can be present in a molar ratio of from 1.0 to 1.5 to the compound of Formula III.
  • the pyridine can be present in a molar ratio of about 1.0, or about 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9 or about 2.0 to the compound of Formula III.
  • the pyridine can be present in a molar ratio of about 1.4 to the compound of Formula III.
  • the sixth reaction mixture can also include a sixth solvent.
  • the sixth solvent can be any suitable solvent including, but not limited to, tetrahydrofuran, 2-methyltetrahydrofuran, toluene, xylene, or combinations thereof.
  • the sixth reaction mixture further comprises a sixth solvent.
  • the sixth solvent can be tetrahydrofuran, 2-methyltetrahydrofuran, toluene, xylene, or combinations thereof.
  • the sixth reaction mixture further comprises 2-methyltetrahydrofuran and toluene.
  • the method of preparing the compound of Formula IIa also includes: (c1) adding an acid and water to the sixth reaction mixture to form a workup mixture; and (c2) distilling the workup mixture to form an intermediate mixture comprising the compound of Formula IIa.
  • the acid of step (c1) can be any suitable acid.
  • the acid comprises formic acid, acetic acid, propanoic acid, butyric acid, hexanoic acid, octanoic acid, trifluoroacetic acid, or mixtures thereof.
  • the acid comprises acetic acid.
  • the sixth reaction mixture further comprises the intermediate mixture comprising the compound of Formula IIa.
  • the method of preparing the compound of Formula IIb-2 comprises the steps of:
  • the present invention provides a method of preparing a compound of Formula I:
  • pyridine is present in a molar ratio of about 1.4 to the compound of Formula III, and wherein the Grignard reagent is present in a molar ratio of 1.65 to the compound of Formula III;
  • compositions of Formula I having a low impurity content In some embodiments, the present invention provides a composition comprising:
  • one or more impurity in an amount of from 0.01 to 1% (w/w) .
  • composition of Formula I can include one or more impurities present in a total amount of 0.01 to 1% (w/w) .
  • the impurity includes at least one of:
  • the impurity present in the composition of the compound Formula I can include the compound of Formula X-4 in an amount of less than 1% (w/w) .
  • the composition of the compound Formula I can include less than 1.0 (w/w) , or less than 0.9, 0.8, 0.75, 0.7, 0.6, 0.5, 0.4, 0.3, 0.25, 0.2, or less than 0.1% (w/w) of the compound of Formula X-4.
  • the composition comprising the compound of Formula I can contain less than 0.5% (w/w) of the compound of Formula X-4.
  • the composition comprising the compound of Formula I can contain less than 0.3% (w/w) of the compound of Formula X-4.
  • the composition comprising the compound of Formula I can contain less than 0.1% (w/w) of the compound of Formula X-4.
  • the impurity present in the composition of the compound of Formula I can include the compound of Formula X-5 in an amount of less than 1% (w/w) .
  • the composition comprising the compound of Formula I can contain less than 1.0 (w/w) , or less than 0.9, 0.8, 0.75, 0.7, 0.6, 0.5, 0.4, 0.3, 0.25, 0.2, or less than 0.1% (w/w) of the compound of Formula X-5.
  • the composition comprising the compound of Formula I can contain less than 1% (w/w) of the compound of Formula X-5.
  • the composition comprising the compound of Formula I can contain less than 0.75% (w/w) of the compound of Formula X-5.
  • the composition comprising the compound of Formula I can contain less than 0.5% (w/w) of the compound of Formula X-5. In some embodiments, the composition comprising the compound of Formula I can contain less than 0.2% (w/w) of the compound of Formula X-5.
  • the impurity present in the composition comprising the compound of Formula I can contain less than 1.0 (w/w) , or less than 0.9, 0.8, 0.75, 0.7, 0.6, 0.5, 0.4, 0.3, 0.25, 0.2, or less than 0.1% (w/w) of the compound of Formula X-6. In some embodiments, the composition comprising the compound of Formula I can contain less than 0.25% (w/w) of the compound of Formula X-6. In some embodiments, the composition comprising the compound of Formula I can contain less than 0.2% (w/w) of the compound of Formula X-6. In some embodiments, the composition comprising the compound of Formula I can contain less than 0.1% (w/w) of the compound of Formula X-6.
  • the impurity comprises: the compound of Formula X-4 in an amount of less than 0.1% (w/w) ; the compound of Formula X-5 in an amount of less than 0.15% (w/w) ; and the compound of Formula X-6 in an amount of less than 0.1% (w/w) .
  • the impurity present in the composition comprising the compound of Formula I can contain methyl-1-methyl-1H-pyrazole-4-sulfonate:
  • the composition comprising the compound of Formula I can contain the impurity of methyl-1-methyl-1H-pyrazole-4-sulfonate in an amount of less than 10 ppm, or less than 9, 8, 7, 6, 5, or less than 4 ppm. In some embodiments, the composition comprising the compound of Formula I can contain the impurity of methyl-1-methyl-1H-pyrazole-4-sulfonate in an amount of less than 8 ppm. In some embodiments, the composition comprising the compound of Formula I can contain the impurity of methyl-1-methyl-1H-pyrazole-4-sulfonate in an amount of less than 6 ppm. In some embodiments, the composition comprising the compound of Formula I can contain the impurity of methyl-1-methyl-1H-pyrazole-4-sulfonate in an amount of less than 4 ppm.
  • the impurity present in the composition comprising the compound of Formula I can contain 1-methyl-1H-pyrazole-4-sulfonyl chloride:
  • the composition comprising compound of Formula I can contain 1-methyl-1H-pyrazole-4-sulfonyl chloride in an amount of less than 10 ppm, or less than 9, 8, 7, 6, 5, or less than 4 ppm.
  • the composition comprising compound of Formula I can contain 1-methyl-1H-pyrazole-4-sulfonyl chloride in an amount of less than 8 ppm.
  • the composition comprising compound of Formula I can contain 1-methyl-1H-pyrazole-4-sulfonyl chloride in an amount of less than 6 ppm.
  • the composition comprising compound of Formula I can contain 1-methyl-1H-pyrazole-4-sulfonyl chloride in an amount of less than 4 ppm.
  • the impurity further comprises: 1-methyl-1H-pyrazole-4-sulfonyl chloride in an amount of less than 4 ppm; and methyl 1-methyl-1H-pyrazole-4-sulfonate in an amount of less than 4ppm.
  • composition comprising the compound of Formula I can also contain one or more of the following impurities:
  • composition comprising the compound of Formula I can also contain one or more of the following impurities:
  • composition comprising the compound of Formula I can also contain a compound having the Formula X-F in an amount of less than 0.30% (w/w) :
  • the present invention also provides crystalline forms of the compound of Formula IIb.
  • the present invention provides a crystalline form of (R) - (1- (4-fluorophenyl) -1, 4, 5, 6, 7, 8-hexahydro-4aH-pyrazolo [3, 4-g] isoquinolin-4a-yl) (4- (trifluoromethyl) pyridin-2-yl) methanone tris-methanesulfonic acid:
  • XRPD pattern having peaks at about 18.2°, 18.3°, and 19.7° 2- ⁇ ⁇ 0.2° 2- ⁇ .
  • the XRPD further comprises peaks at about 9.9°, 16.5°, and 17.6° 2- ⁇ ⁇ 0.2° 2- ⁇ . In some embodiments, the XRPD further comprises peaks at about 5.0°, 14.5°, 17.9°, 19.0°, 20.8°, 22.9°, 23.4°, and 25.3° 2- ⁇ ⁇ 0.2° 2- ⁇ . In some embodiments, the XRPD comprises peaks at about 5.0°, 9.9°, 14.5°, 16.5°, 17.6°, 17.9°, 18.2°, 18.3°, 19.0°, 19.7°, 20.8°, 22.9°, 23.4°, and 25.3° 2- ⁇ ⁇ 0.2° 2- ⁇ . In some embodiments, crystalline form is characterized by the XRPD pattern substantially as set forth in FIG. 2.
  • the crystalline form is characterized by a differential scanning calorimetry (DSC) thermogram having an endotherm with an onset of about 167°. In some embodiments, the crystalline form is characterized by a DSC thermogram substantially as shown in FIG. 3.
  • DSC differential scanning calorimetry
  • the present invention provides a crystalline form of (R) - (1- (4-fluorophenyl) -1, 4, 5, 6, 7, 8-hexahydro-4aH-pyrazolo [3, 4-g] isoquinolin-4a-yl) (4- (trifluoromethyl) pyridin-2-yl) methanone oxalic acid:
  • XRPD pattern having peaks at about 6.1, 8.4, 10.6 and 15.6° 2- ⁇ ⁇ 0.2° 2- ⁇ .
  • the XRPD further comprises peaks at about 12.3, 13.0, and 25.3° 2- ⁇ ⁇ 0.2° 2- ⁇ . In some embodiments, the XRPD further comprises peaks at about 16.2, 17.1, 18.2, 19.9, 21.7, 22.9, 23.7, and 24.6° 2- ⁇ ⁇ 0.2° 2- ⁇ . In some embodiments, the XRPD comprises peaks at about 6.1, 8.4, 10.6, 12.3, 13.0, 15.6, 16.2, 17.1, 18.2, 19.9, 21.7, 22.9, 23.7, 24.6 and 25.3° 2- ⁇ ⁇ 0.2° 2- ⁇ . In some embodiments, the crystalline form is characterized by an X-ray powder diffraction (XRPD pattern substantially as set forth in FIG. 5.
  • the crystalline form is characterized by a differential scanning calorimetry (DSC) thermogram having an endotherm with an onset of about 168°. In some embodiments, the crystalline form is characterized by a DSC thermogram substantially as shown in FIG. 6.
  • DSC differential scanning calorimetry
  • the present invention provides a crystalline form of (R) - (1- (4-fluorophenyl) -1, 4, 5, 6, 7, 8-hexahydro-4aH-pyrazolo [3, 4-g] isoquinolin-4a-yl) (4- (trifluoromethyl) pyridin-2-yl) methanone tris-hydrochloric acid:
  • XRPD pattern having peaks at about 15.3, 22.0, 23.1, and 24.5° 2- ⁇ ⁇ 0.2° 2- ⁇ .
  • the XRPD further comprises peaks at about 7.0, 13.5, 14.8, 17.7, 18.3, 19.2, 23.5, and 25.2° 2- ⁇ ⁇ 0.2° 2- ⁇ . In some embodiments, the XRPD further comprises peaks at about 8.1, 11.5, 21.2, 26.9, 27.2, 28.1, 30.1, and 32.4° 2- ⁇ ⁇ 0.2° 2- ⁇ . In some embodiments, the XRPD comprises peaks at about 7.0, 8.1, 11.5, 13.5, 14.8, 15.3, 17.7, 18.3, 19.2, 21.2, 22.0, 23.1, 23.5, 24.5, 25.2, 26.9, 27.2, 28.1, 30.1, and 32.4° 2- ⁇ ⁇ 0.2° 2- ⁇ . In some embodiments, the crystalline form is characterized by an X-ray powder diffraction (XRPD pattern substantially as set forth in FIG. 8.
  • the crystalline form is characterized by a differential scanning calorimetry (DSC) thermogram having an endotherm with an onset of about 215°. In some embodiments, the crystalline form is characterized by a DSC thermogram substantially as shown in FIG. 9.
  • DSC differential scanning calorimetry
  • the present invention provides a pharmaceutical composition comprising a low impurity composition of the present invention and a pharmaceutically acceptable excipient.
  • the low impurity compositions of the present invention can be prepared and administered in a wide variety of oral, parenteral and topical dosage forms.
  • Oral preparations include tablets, pills, powder, dragees, capsules, liquids, lozenges, gels, syrups, slurries, suspensions, etc., suitable for ingestion by the patient.
  • the low impurity compositions of the present invention can also be administered by injection, that is, intravenously, intramuscularly, intracutaneously, subcutaneously, intraduodenally, or intraperitoneally.
  • the compounds described herein can be administered by inhalation, for example, intranasally. Additionally, the low impurity compositions of the present invention can be administered transdermally.
  • the compounds of formula I of this invention can also be administered by in intraocular, intravaginal, and intrarectal routes including suppositories, insufflation, powders and aerosol formulations (for examples of steroid inhalants, see Rohatagi, J. Clin. Pharmacol. 35: 1187-1193, 1995; Tjwa, Ann. Allergy Asthma Immunol. 75: 107-111, 1995) .
  • the present invention also provides pharmaceutical compositions including one or more pharmaceutically acceptable carriers and/or excipients and a compound of formula I.
  • pharmaceutically acceptable carriers can be either solid or liquid.
  • Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules.
  • a solid carrier can be one or more substances, which may also act as diluents, flavoring agents, surfactants, binders, preservatives, tablet disintegrating agents, or an encapsulating material. Details on techniques for formulation and administration are well described in the scientific and patent literature, see, e.g., the latest edition of Remington’s Pharmaceutical Sciences, Maack Publishing Co, Easton PA ( “Remington’s” ) .
  • the carrier is a finely divided solid, which is in a mixture with the finely divided active component.
  • the active component is mixed with the carrier having the necessary binding properties and additional excipients as required in suitable proportions and compacted in the shape and size desired.
  • the powders, capsules and tablets preferably contain from 5%or 10%to 70%of the active compound.
  • Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like.
  • the term “preparation” is intended to include the formulation of the active compound with encapsulating material as a carrier providing a capsule in which the active component with or without other exceipients, is surrounded by a carrier, which is thus in association with it.
  • cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid dosage forms suitable for oral administration.
  • Suitable solid excipients are carbohydrate or protein fillers including, but not limited to sugars, including lactose, sucrose, mannitol, or sorbitol; starch from corn, wheat, rice, potato, or other plants; cellulose such as methyl cellulose, hydroxypropylmethyl-cellulose, or sodium carboxymethylcellulose; and gums including arabic and tragacanth; as well as proteins such as gelatin and collagen.
  • disintegrating or solubilizing agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, alginic acid, or a salt thereof, such as sodium alginate.
  • Dragee cores are provided with suitable coatings such as concentrated sugar solutions, which may also contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures.
  • Dyestuffs or pigments may be added to the tablets or dragee coatings for product identification or to characterize the quantity of active compound (i.e., dosage) .
  • Pharmaceutical preparations of the invention can also be used orally using, for example, push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a coating such as glycerol or sorbitol.
  • Push-fit capsules can contain the compounds of formula I mixed with a filler or binders such as lactose or starches, lubricants such as talc or magnesium stearate, and, optionally, stabilizers.
  • a filler or binders such as lactose or starches
  • lubricants such as talc or magnesium stearate
  • stabilizers optionally, stabilizers.
  • the compounds of formula I may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycol with or without stabilizers.
  • a low melting wax such as a mixture of fatty acid glycerides or cocoa butter
  • the active component is dispersed homogeneously therein, as by stirring.
  • the molten homogeneous mixture is then poured into convenient sized molds, allowed to cool, and thereby to solidify.
  • Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water/propylene glycol solutions.
  • liquid preparations can be formulated in solution in aqueous polyethylene glycol solution.
  • solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for oral administration.
  • liquid forms include solutions, suspensions, and emulsions.
  • These preparations may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.
  • Oil suspensions can be formulated by suspending the compound of formula I in a vegetable oil, such as arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin; or a mixture of these.
  • the oil suspensions can contain a thickening agent, such as beeswax, hard paraffin or cetyl alcohol.
  • Sweetening agents can be added to provide a palatable oral preparation, such as glycerol, sorbitol or sucrose.
  • These formulations can be preserved by the addition of an antioxidant such as ascorbic acid.
  • an injectable oil vehicle see Minto, J. Pharmacol. Exp. Ther. 281: 93-102, 1997.
  • the pharmaceutical formulations of the invention can also be in the form of oil-in-water emulsions.
  • the oily phase can be a vegetable oil or a mineral oil, described above, or a mixture of these.
  • Suitable emulsifying agents include naturally-occurring gums, such as gum acacia and gum tragacanth, naturally occurring phosphatides, such as soybean lecithin, esters or partial esters derived from fatty acids and hexitol anhydrides, such as sorbitan mono-oleate, and condensation products of these partial esters with ethylene oxide, such as polyoxyethylene sorbitan mono-oleate.
  • the emulsion can also contain sweetening agents and flavoring agents, as in the formulation of syrups and elixirs. Such formulations can also contain a demulcent, a preservative, or a coloring agent.
  • the compounds of formula I of the invention can be delivered by transdermally, by a topical route, formulated as applicator sticks, solutions, suspensions, emulsions, gels, creams, ointments, pastes, jellies, paints, powders, and aerosols.
  • microspheres can be administered via intradermal injection of drug –containing microspheres, which slowly release subcutaneously (see Rao, J. Biomater Sci. Polym. Ed. 7: 623-645, 1995; as biodegradable and injectable gel formulations (see, e.g., Gao Pharm. Res. 12: 857-863, 1995) ; or, as microspheres for oral administration (see, e.g., Eyles, J. Pharm. Pharmacol. 49: 669-674, 1997) . Both transdermal and intradermal routes afford constant delivery for weeks or months.
  • the formulations of the compounds of formula I of the invention can be delivered by the use of liposomes which fuse with the cellular membrane or are endocytosed, i.e., by employing ligands attached to the liposome, or attached directly to the oligonucleotide, that bind to surface membrane protein receptors of the cell resulting in endocytosis.
  • liposomes particularly where the liposome surface carries ligands specific for target cells, or are otherwise preferentially directed to a specific organ, one can focus the delivery of the GR modulator into the target cells in vivo. (See, e.g., Al-Muhammed, J. Microencapsul. 13: 293-306, 1996; Chonn, Curr. Opin. Biotechnol. 6: 698-708, 1995; Ostro, Am. J. Hosp. Pharm. 46: 1576-1587, 1989) .
  • the pharmaceutical preparation is preferably in unit dosage form.
  • the preparation is subdivided into unit doses containing appropriate quantities of the active component.
  • the unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules.
  • the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.
  • the quantity of active component in a unit dose preparation may be varied or adjusted from 0.1 mg to 10000 mg, more typically 1.0 mg to 1000 mg, most typically 10 mg to 500 mg, according to the particular application and the potency of the active component.
  • the dose can be 50 mg, or 100, 150, 200, 250, 300, 350, 400, 450, or 500 mg.
  • the composition can, if desired, also contain other compatible therapeutic agents.
  • the dosage regimen also takes into consideration pharmacokinetics parameters well known in the art, i.e., the rate of absorption, bioavailability, metabolism, clearance, and the like (see, e.g., Hidalgo-Aragones (1996) J. Steroid Biochem. Mol. Biol. 58: 611-617; Groning (1996) Pharmazie 51: 337-341; Fotherby (1996) Contraception 54: 59-69; Johnson (1995) J. Pharm. Sci. 84: 1144-1146; Rohatagi (1995) Pharmazie 50: 610-613; Brophy (1983) Eur. J. Clin. Pharmacol. 24: 103-108; the latest Remington’s, supra) .
  • the state of the art allows the clinician to determine the dosage regimen for each individual patient, GR and /or MR modulator and disease or condition treated.
  • the pharmaceutical formulations for oral administration of the compound of formula I is in a daily amount of between about 0.5 to about 30 mg per kilogram of body weight per day.
  • dosages are from about 1 mg to about 20 mg per kg of body weight per patient per day are used.
  • Lower dosages can be used, particularly when the drug is administered to an anatomically secluded site, such as the cerebral spinal fluid (CSF) space, in contrast to administration orally, into the blood stream, into a body cavity or into a lumen of an organ.
  • CSF cerebral spinal fluid
  • Substantially higher dosages can be used in topical administration.
  • Actual methods for preparing formulations including the compound of formula I for parenteral administration are known or apparent to those skilled in the art and are described in more detail in such publications as Remington’s, supra. See also Nieman, In “Receptor Mediated Antisteroid Action, ” Agarwal, et al., eds., De Gruyter, New York (1987) .
  • the compounds described herein can be used in combination with one another, with other active agents known to be useful in modulating a glucocorticoid receptor, or with adjunctive agents that may not be effective alone, but may contribute to the efficacy of the active agent.
  • co-administration includes administering one active agent within 0.5, 1, 2, 4, 6, 8, 10, 12, 16, 20, or 24 hours of a second active agent.
  • Co-administration includes administering two active agents simultaneously, approximately simultaneously (e.g., within about 1, 5, 10, 15, 20, or 30 minutes of each other) , or sequentially in any order.
  • co-administration can be accomplished by co-formulation, i.e., preparing a single pharmaceutical composition including both active agents.
  • the active agents can be formulated separately.
  • the active and/or adjunctive agents may be linked or conjugated to one another.
  • a pharmaceutical composition including a compound of formula I of the invention After a pharmaceutical composition including a compound of formula I of the invention has been formulated in one or more acceptable carriers, it can be placed in an appropriate container and labeled for treatment of an indicated condition.
  • labeling would include, e.g., instructions concerning the amount, frequency and method of administration.
  • compositions of the present invention are useful for parenteral administration, such as intravenous (IV) administration or administration into a body cavity or lumen of an organ.
  • the formulations for administration will commonly comprise a solution of the compositions of the present invention dissolved in one or more pharmaceutically acceptable carriers.
  • sterile fixed oils can conventionally be employed as a solvent or suspending medium.
  • any bland fixed oil can be employed including synthetic mono-or diglycerides.
  • fatty acids such as oleic acid can likewise be used in the preparation of injectables. These solutions are sterile and generally free of undesirable matter.
  • These formulations may be sterilized by conventional, well known sterilization techniques.
  • the formulations may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions such as pH adjusting and buffering agents, tonicity adjusting agents, e.g., sodium acetate, sodium chloride, potassium chloride, calcium chloride, sodium lactate and the like.
  • concentration of the compositions of the present invention in these formulations can vary widely, and will be selected primarily based on fluid volumes, viscosities, body weight, and the like, in accordance with the particular mode of administration selected and the patient’s needs.
  • the formulation can be a sterile injectable preparation, such as a sterile injectable aqueous or oleaginous suspension. This suspension can be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents.
  • the sterile injectable preparation can also be a sterile injectable solution or suspension in a nontoxic parenterally-acceptable diluent or solvent, such as a solution of 1, 3-butanediol.
  • the formulations of the compositions of the present invention can be delivered by the use of liposomes which fuse with the cellular membrane or are endocytosed, i.e., by employing ligands attached to the liposome, or attached directly to the oligonucleotide, that bind to surface membrane protein receptors of the cell resulting in endocytosis.
  • liposomes particularly where the liposome surface carries ligands specific for target cells, or are otherwise preferentially directed to a specific organ, one can focus the delivery of the compositions of the present invention into the target cells in vivo. (See, e.g., Al-Muhammed, J. Microencapsul. 13: 293-306, 1996; Chonn, Curr. Opin. Biotechnol. 6: 698-708, 1995; Ostro, Am. J. Hosp. Pharm. 46: 1576-1587, 1989) .
  • the present invention provides a method of treating a disorder or condition through modulating a glucocorticoid receptor, the method comprising administering to a subject in need of such treatment, a therapeutically effective amount of any one of the low impurity compositions of the present invention, or a pharmaceutical composition of the present invention, thereby treating the disorder or condition.
  • the present invention provides a method of treating a disorder or condition through antagonizing a glucocorticoid receptor, the method comprising administering to a subject in need of such treatment, an effective amount of any one of the low impurity compositions of the present invention, or a pharmaceutical composition of the present invention.
  • the disorder or condition is selected from the group consisting of amyotrophic lateral sclerosis (ALS) , obesity, diabetes, cardiovascular disease, hypertension, Syndrome X, depression, anxiety, glaucoma, neurodegeneration, Alzheimer’s disease, Parkinson’s disease, Cushing’s Syndrome, Cushing Disease, cancer, liver disease, osteoporosis, muscle frailty, a disorder caused by adrenal disease-related cortisol excess, addiction, psychosis, anorexia, cachexia, post-traumatic stress syndrome, post-surgical bone fracture, a GR-related metabolic disorders, major psychotic depression, mild cognitive impairment, dementia, hyperglycemia, a stress disorder, antipsychotic induced weight gain, delirium, cognitive impairment in depressed patients, postpartum psychosis, postpartum depression, and a neurological disorder in a premature infant.
  • ALS amyotrophic lateral sclerosis
  • the method includes administering one or more second agents (e.g. therapeutic agents) . In some embodiments, the method includes administering one or more second agents (e.g. therapeutic agents) in a therapeutically effective amount. In some embodiments, the second agent is an agent known to be useful in modulating a glucocorticoid receptor.
  • the second agent is an agent for treating amyotrophic lateral sclerosis (ALS) , obesity, diabetes, cardiovascular disease, hypertension, Syndrome X, depression, anxiety, glaucoma, neurodegeneration, Alzheimer’s disease, Parkinson’s disease, Cushing’s Syndrome, Cushing Disease, cancer, liver disease, osteoporosis, muscle frailty, a disorder caused by adrenal disease-related cortisol excess, addiction, psychosis, anorexia, cachexia, post-traumatic stress syndrome, post-surgical bone fracture, a GR-related metabolic disorders, major psychotic depression, mild cognitive impairment, dementia, hyperglycemia, a stress disorder, antipsychotic induced weight gain, delirium, cognitive impairment in depressed patients, postpartum psychosis, postpartum depression, and a neurological disorder in a premature infant.
  • ALS amyotrophic lateral sclerosis
  • the second agent is an agent for treating major psychotic depression, stress disorders or antipsychotic induced weight gain. In some embodiments, the second agent is an agent for treating nonalcoholic fatty liver disease and/or nonalcoholic steatohepatitis. In some embodiments, the second agent is an agent for treating an addiction disorder. In some embodiments, the second agent is an agent for treating cancer. In some embodiments, the second agent is an anti-cancer agent. In some embodiments, the second agent is a chemotherapeutic.
  • any one of the low impurity compositions of the present invention, or a pharmaceutical composition of the present invention can be used for a method of treating a disorder or condition through modulating a glucocorticoid receptor.
  • any one of the low impurity compositions of the present invention, or a pharmaceutical composition of the present invention can be used for a method of treating a disorder or condition through antagonizing a glucocorticoid receptor.
  • any one of the low impurity compositions of the present invention, or a pharmaceutical composition of the present invention can be used in the manufacture of a medicament for treating a disorder or condition through modulating a glucocorticoid receptor.
  • any one of the low impurity compositions of the present invention, or a pharmaceutical composition of the present invention can be used in the manufacture of a medicament for treating a disorder or condition through antagonizing a glucocorticoid receptor.
  • X-ray Powder Diffraction X-ray Powder Diffraction
  • XRPD analyses were performed using a Panalytical Xpert Pro diffractometer equipped with a Cu X-ray tube and a Pixcel detector system. The isothermal samples were analysed in transmission mode and held between low density polyethylene films.
  • the XRPD program used included the following parameters: (1) range 3-40°2 ⁇ , (2) step size 0.013°, (3) counting time 99sec, and (4) about 22min run time.
  • XRPD patterns were sorted using HighScore Plus 2.2c software.
  • DSC Differential Scanning Calorimetry
  • the reaction steps of the present invention can be performed for any suitable reaction time.
  • the reaction time can be for minutes, hours, or days.
  • the reaction time can be for several hours, such as at least eight hours.
  • the reaction time can be for several hours, such as at least overnight.
  • the reaction time can be for several days.
  • the reaction time can be for at least two hours.
  • the reaction time can be for at least eight hours.
  • the reaction time can be for at least several days.
  • the reaction time can be for about two hours, or for about 4 hours, or for about 6 hours, or for about 8 hours, or for about 10 hours, or for about 12 hours, or for about 14 hours, or for about 16 hours, or for about 18 hours, or for about 20 hours, or for about 22 hours, or for about 24 hours. In some embodiments, the reaction time can be for about 1 day, or for about two days, or for about three days, or for about four days, or for about five days, or for about six days, or for about a week, or for about more than a week.
  • reaction steps of the present invention can be performed at any suitable reaction temperature.
  • Representative temperatures include, but are not limited to, below room temperature, at room temperature, or above room temperature.
  • Other temperatures useful in the methods of the present invention include from about -40 °C to about 65 °C, or from about room temperature to about 40 °C, or from about 40 °C to about 65 °C, or from about 40 °C to about 60 °C.
  • the reaction mixture can be at a temperature of about room temperature, or at a temperature of about 15°C, or at about 20 °C, or at about 25 °C or at about 30 °C, or at about 35 °C, or at about 40 °C, or at about 45 °C, or at about 50 °C, or at about 55 °C, or at about 60 °C, or at about 65 °C.
  • the reaction is quenched by the addition of 0.28 parts acetic acid in 10 parts water.
  • the solution is stirred then allowed to settle.
  • the aqueous phase is discarded and the organic phase washed with 12 parts aqueous hydrochloric acid.
  • the aqueous phase is discarded and the organic phase is washed with 12 parts water.
  • the aqueous phase is discarded.
  • the product is dried through azeotropic distillation at ⁇ 50C (KF, ⁇ 0.1%water; HPLC, ⁇ 20ppm 2-MeTHF) .
  • the product is isolated in toluene (5-8%w/w) and affords 1.1 –1.3 parts (90 –100%molar yield) .
  • the characterization data of the title compound matched that of Intermediate 29 of U.S. Patent No. 8,859,774.
  • the target compound was prepared using the following steps.
  • the toluene solution of 1.0 part of the product from Example 1 is added to a vessel.
  • 1.0 –1.2 parts hydrogen bromide gas is added at a temperature of -5 to 5°C until the reaction is complete (HPLC, ⁇ 1.0%the product from Example 1 remains) .
  • the mixture is transferred to a filter dryer and washed with at least 2.6 parts toluene at a temperature of -5 to 5°C.
  • the solid is dried under vacuum/nitrogen at -5 to 10°C for at least 24 hours and sampled every 12-24 hours (GC, ⁇ 25%toluene remains) .
  • the tris-hydrobromic acid compound is isolated and affords 1.1 –1.3 parts (85 –100%molar yield) .
  • Example 2 The product of Example 2 was purified by the following methods.
  • the packed column was equilibrated with 1-2 column volumes of Mobile Phase A. Crude relacorilant (1.0 –1.5 kg) in solution was loaded onto the chromatography column at a rate of 3 L/min. The product was eluted from the column using a gradient of Mobile Phase B to Mobile Phase C over 100 minutes at a flow rate of 4.5 L/min. Fractionation was performed by separating the column eluant into multiple collection tanks in accordance with the established use test collection times. Following column fractionation, the column was washed with Buffer C for 10 minutes at a flow rate of 6.5 L/min to regenerate the packing material.
  • the relacorilant fraction pool is further purified as described in the following process.
  • a solvent exchange is performed with MTBE concentrated under vacuum at ⁇ 50 °C to ⁇ 11 parts by volume of a relacorilant in MTBE solution (GC, ⁇ 5%ethyl acetate) .
  • the relacorilant solution is filtered through a CUNO cartridge filter (HPLC, ⁇ 0.30 Formula X-5, ⁇ 0.20 Formula X-6, ⁇ 0.15 Formula X-4, ⁇ 0.10%unknown impurities) .
  • the relacorilant in MTBE solution is slowly added to 10 parts heptane at 30 to 40°Cand the solution is cooled to -5 to 5°C to precipitate the relacorilant.
  • the relacorilant precipitate is collected and washed with ⁇ 2 parts heptane.
  • the wet cake is dried at ⁇ 50°C for ⁇ 4hr (GC, ⁇ 15%MTBE, ⁇ 15%heptane, ⁇ 4ppm 1, 4-dibromopentane) .
  • the purified relacorilant is isolated and affords 0.60 –0.90 parts (60 –90%molar yield) purified relacorilant.
  • the purified relacorilant was dissolved in 13.6 parts methanol.
  • the methanol solution was concentrated under vacuum at ⁇ 50 °C to ⁇ 9 parts by volume of a solution of relacorilant in MTBE (GC, ⁇ 300ppm MTBE, ⁇ 300ppm heptane) .
  • the solution was slowly added through at 0.22 ⁇ m in-line filter into 15 parts water to precipitate the relacorilant.
  • the relacorilant precipitate was collected by filtration and washed with at least 5 parts water (HPLC, ⁇ 4 ppm 1-Methyl-1H-pyrazole-4-sulfonyl chloride, ⁇ 4 ppm 1-Methyl-1H-pyrazole-4-sulfonate, ⁇ 50ppm formic acid) .
  • Relacorilant was then dried under vacuum (KF, ⁇ 1.1%; GC, ⁇ 4500ppm isopropyl acetate, ⁇ 4500ppm acetone, ⁇ 370ppm acetonitrile, ⁇ 4500ppm ethyl acetate, ⁇ 2700ppm methanol, ⁇ 5000ppm heptane, ⁇ 5000ppm MTBE) .
  • the target compound was prepared using the following steps.
  • Step 1 relates to the addition of 2-Bromo-4- (trifluoromethyl) pyridine (3.0 equiv. ) to 6- (tert-butyl) 4a-methyl (R) -1- (4-fluorophenyl) -1, 4, 7, 8-tetrahydro-6H-pyrazolo [3, 4-g] isoquinoline-4a, 6 (5H) -dicarboxylate (Compound 9; 1.0 equiv. ) facilitated through halo-metal exchange using the Grignard reagent iPrMgCl (3.05 equiv. ) .
  • the intermediate hemi-ketal is converted to the ketone and the Step 1 product is isolated as a solution in toluene and used directly in the next step.
  • Step 24 Charge the contents of the plastic lined drum from Steps 10 and 13 containing Compound 9 toluene solution to the reactor via the reagent addition line over at least 20 minutes, whilst maintaining a batch temperature below 5 °C.
  • Step 2 relates to a Boc deprotection achieved using methane sulfonic acid (4.5 equiv. ) and subsequent product isolation as the Tris MSA salt by means of crystallisation from the reaction mixture initiated using 0.25mol%of Step 2 tris MSA salt seed.
  • Step 1 Product 70 Kg, 8.90 Kg corrected
  • Step 2 Charge the reactor with Step 2 Product seed (30 g) .
  • Step 17 Remove a sample from the reactor. Check the LCAP (liquid chromatography area percentage) of the Step 2 Product free base with respect to Step 1 Product (Result: >99%) .
  • Tetrahydrofuran (24 Kg) to the reactor via the solvent addition line, using a dosing pump, and start the stirrer.
  • Tetrahydrofuran 24 Kg
  • Step 2 product Tris MSA salt
  • Step 2 product Tris MSA salt
  • Triethylamine (0.443 Kg) using a dosing pump (over at least 5 minutes) , whilst maintaining a batch temperature of 5 °C.
  • Step 38 Concentrate the relacorilant solution from Step 37, to achieve a final volume of approximately 1.5 L.
  • Step 40 Concentrate the relacorilant solution from Step 39, to achieve a final volume of approximately 3.0 L.
  • the impurity profile of the compounds of Example 3 and Example 4 was determined.
  • a vessel was charged with 1 (16.0 g, 95.1 wt%, 28.05 mmol, 1.0 eq. ) and MeCN (80 mL, 5 vol. ) and cooled to 0 °C.
  • reaction mixture was warmed to room temperature and aged for 20 h. Reaction conversion was 98%as determined by HPLC LCAP (FFCAM method) .
  • reaction mixture was seeded with 2 ⁇ HCl (ca. 5 mg) and aged for 20 min at room temperature.
  • DIPEA (7.1 mL, 44.4 mmol, 1.5 eq. ) was added over 45 min at room temperature using a syringe pump and aged for an additional 30 min. Liquor loss of 2 was 19.9 mg/mL as determine by HPLC.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PCT/CN2020/139524 2020-12-25 2020-12-25 Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators Ceased WO2022134033A1 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
PCT/CN2020/139524 WO2022134033A1 (en) 2020-12-25 2020-12-25 Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
KR1020237024682A KR20230124985A (ko) 2020-12-25 2021-12-22 헤테로아릴-케톤 융합 아자데칼린 글루코코르티코이드수용체 조절제 제조 방법
US17/560,048 US12152028B2 (en) 2020-12-25 2021-12-22 Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
MX2023007404A MX2023007404A (es) 2020-12-25 2021-12-22 Métodos para preparar moduladores del receptor de glucocorticoides de azadecalina fusionados con heteroaril-cetona.
CN202180091897.1A CN116867780A (zh) 2020-12-25 2021-12-22 制备杂芳基-酮稠合的氮杂萘烷糖皮质激素受体调节剂的方法
EP21912180.3A EP4267577A4 (en) 2020-12-25 2021-12-22 PROCESSES FOR PREPARING HETEROARYL KETONE-FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS
CA3202354A CA3202354A1 (en) 2020-12-25 2021-12-22 Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
AU2021410756A AU2021410756B2 (en) 2020-12-25 2021-12-22 Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
PCT/US2021/064947 WO2022140600A1 (en) 2020-12-25 2021-12-22 Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
JP2023538962A JP7720914B2 (ja) 2020-12-25 2021-12-22 ヘテロアリール－ケトン縮合アザデカリングルココルチコイド受容体調節因子を調製する方法
IL304005A IL304005A (en) 2020-12-25 2021-12-22 Methods for the preparation of AZADECALIN fused heteroaryl-ketone glucocorticoid receptor modulators
US18/920,639 US20250145620A1 (en) 2020-12-25 2024-10-18 Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
AU2025203341A AU2025203341B2 (en) 2020-12-25 2025-05-09 Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2020/139524 WO2022134033A1 (en) 2020-12-25 2020-12-25 Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators

Publications (1)

Publication Number Publication Date
WO2022134033A1 true WO2022134033A1 (en) 2022-06-30

Family

ID=82157262

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/CN2020/139524 Ceased WO2022134033A1 (en) 2020-12-25 2020-12-25 Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
PCT/US2021/064947 Ceased WO2022140600A1 (en) 2020-12-25 2021-12-22 Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2021/064947 Ceased WO2022140600A1 (en) 2020-12-25 2021-12-22 Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators

Country Status (10)

Country Link
US (2) US12152028B2 (enExample)
EP (1) EP4267577A4 (enExample)
JP (1) JP7720914B2 (enExample)
KR (1) KR20230124985A (enExample)
CN (1) CN116867780A (enExample)
AU (2) AU2021410756B2 (enExample)
CA (1) CA3202354A1 (enExample)
IL (1) IL304005A (enExample)
MX (1) MX2023007404A (enExample)
WO (2) WO2022134033A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12152028B2 (en) 2020-12-25 2024-11-26 Corcept Therapeutics Incorporated Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
US12370188B2 (en) 2022-10-06 2025-07-29 Corcept Therapeutics Incorporated Formulations of dazucorilant, a glucocorticoid receptor modulator

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013177559A2 (en) * 2012-05-25 2013-11-28 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
WO2015077530A1 (en) * 2013-11-25 2015-05-28 Corcept Therapeutics, Inc. Octahydro fused azadecalin glucocorticoid receptor modulators
WO2017151613A1 (en) * 2016-03-01 2017-09-08 Corcept Therapeutics, Inc. The use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors
WO2020172501A1 (en) * 2019-02-22 2020-08-27 Corcept Therapeutics Incorporated Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL72729A (en) 1983-09-26 1988-02-29 Lilly Co Eli Trans(+_)octahydropyrazole-ring alkylated pyrazoloquinolines,their preparation and pharmaceutical compositions containing them
GB8828669D0 (en) 1988-12-08 1989-01-11 Lilly Industries Ltd Organic compounds
DE69430373T2 (de) 1993-08-06 2002-12-12 Smithkline Beecham S.P.A., Baranzate Di Bollate Hydroisochinolinderivate
US5696130A (en) 1994-12-22 1997-12-09 Ligand Pharmaceuticals Incorporated Tricyclic steroid receptor modulator compounds and methods
EP1061919A4 (en) 1998-03-10 2002-09-04 Res Triangle Inst NOVEL OPIOUS COMPOUNDS AND PROCESSES FOR THEIR PREPARATION AND USE
US6166013A (en) 1998-07-30 2000-12-26 Abbott Laboratories Glucocortiocoid-selective agents
WO2000043017A1 (en) 1999-01-21 2000-07-27 Steroidogenesis Inhibitors International Composition of anti-hiv drugs and anti-cortisol compounds and method for decreasing the side effects of anti-hiv drugs in a human
GB9911053D0 (en) 1999-05-12 1999-07-14 Pharmacia & Upjohn Spa 4,5,6,7-tetrahydroindazole derivatives process for their preparation and their use as antitumour agents
GB0010683D0 (en) 2000-05-03 2000-06-28 Univ Bristol Cancer therapy
US6583180B2 (en) 2001-02-14 2003-06-24 Abbott Laboratories Glucocorticoid receptor modulators
AU2002258399A1 (en) 2001-02-16 2002-09-19 Medical College Of Georgia Research Institute, Inc. Use of trail and antiprogestins for treating cancer
AU2002355929A1 (en) 2001-07-17 2003-03-03 Smithkline Beecham Corporation Crystallized glucocorticoid receptor ligand binding domain polypeptide and screening methods employing same
JP2004537563A (ja) 2001-07-23 2004-12-16 コーセプト セラピューティクス， インコーポレイテッド 抗神経病薬誘導性体重増加を予防するための方法
CN1556708A (zh) 2001-08-31 2004-12-22 �Ƹ��� 抑制成年唐氏综合症患者认知退化的方法
AU2003214879B2 (en) 2002-01-22 2008-02-07 The Regents Of The University Of California Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof
US20030162695A1 (en) 2002-02-27 2003-08-28 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability
JP2005535664A (ja) 2002-07-02 2005-11-24 コーセプト セラピューティクス， インコーポレイテッド インターフェロン−α治療に関連した精神病を処置するための方法
CA2499150A1 (en) 2002-09-20 2004-04-01 Merck & Co., Inc. Octahydro-2-h-naphtho[1,2-f] indole-4-carboxamide derivatives as selective glucocorticoid receptor modulators
US20040229855A1 (en) 2003-02-04 2004-11-18 Corcept Therapeutics, Inc. Antiglucocorticoids for the treatment of postpartum psychosis
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
AU2004270154A1 (en) 2003-09-03 2005-03-17 Wyeth Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and its pharmaceutical compositions containing the same
DK1761497T3 (da) 2004-01-09 2008-11-03 Corcept Therapeutics Inc Azadecalinglucocorticoidreceptormodulatorer
AU2005217646A1 (en) 2004-02-26 2005-09-09 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services A novel cofactor that modulates steroid receptor activities
AU2005222421B2 (en) 2004-03-09 2010-09-23 Corcept Therapeutics, Inc. Fused ring azadecalin glucocorticoid receptor modulators
JP4958774B2 (ja) 2004-07-02 2012-06-20 コーセプト セラピューティクス， インコーポレイテッド 改変されたピリミジン糖質コルチコイドレセプター調節因子
EP2757099B1 (en) 2005-05-12 2017-08-23 AbbVie Bahamas Limited Apoptosis promoters
US7790745B2 (en) 2005-10-21 2010-09-07 Bristol-Myers Squibb Company Tetrahydroisoquinoline LXR Modulators
US7640389B2 (en) 2006-02-28 2009-12-29 Freescale Semiconductor, Inc. Non-volatile memory having a multiple block erase mode and method therefor
EP1932843A1 (en) 2006-12-14 2008-06-18 sanofi-aventis Sulfonyl-phenyl-2H-(1,2,4) oxadiazole-5-one derivatives, processes for their preparation and their use as pharmaceuticals
JP2011503111A (ja) 2007-11-12 2011-01-27 バイパー サイエンシズ，インコーポレイティド Ｐａｒｐ阻害剤単独又は抗腫瘍剤との組み合わせによる乳がんの治療
US20120022121A1 (en) 2007-11-29 2012-01-26 Dalton James T Indoles, derivatives and analogs thereof and uses therefor
US20090156672A1 (en) 2007-12-17 2009-06-18 Northwestern University Substituted Phenyl Aziridine Precursor Analogs as Modulators of Steroid Receptor Activities
US8003689B2 (en) 2008-06-20 2011-08-23 Gtx, Inc. Metabolites of selective androgen receptor modulators and methods of use thereof
CA2728563C (en) 2008-07-01 2017-05-30 Corcept Therapeutics, Inc. Use of mifepristone for the treatment of amyotrophic lateral sclerosis
US20100135956A1 (en) 2008-11-21 2010-06-03 Auspex Pharmaceuticals, Inc. Steroid modulators of progesterone receptor and/or glucocorticoid receptor
JP5637568B2 (ja) 2009-05-12 2014-12-10 コーセプト セラピューティクス， インコーポレイテッド 固体形態および調製のためのプロセス
EP2545173A2 (en) 2010-03-12 2013-01-16 Sarepta Therapeutics, Inc. Antisense modulation of nuclear hormone receptors
US8710035B2 (en) 2010-03-24 2014-04-29 The University Of Chicago Methods and compositions related to glucocorticoid receptor antagonists and breast cancer
MX2013002186A (es) 2010-08-27 2013-06-28 Corcept Therapeutics Inc Moduladores de azadecalina de piridil-amina fusionada.
US9314473B2 (en) 2011-02-03 2016-04-19 Pop Test Oncology Limited Liability Company System and method for diagnosis and treatment
EP2671086B1 (en) 2011-02-03 2018-04-25 Pop Test Oncology LLC System and method for diagnosis and treatment
KR101925955B1 (ko) 2011-03-18 2018-12-06 코어셉트 쎄라퓨틱스, 잉크. 피리미딘 사이클로헥실 글루코코르티코이드 수용체 조절제
WO2013039916A1 (en) 2011-09-12 2013-03-21 The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services Compositions for and methods of treatment and enhanced detection of non-pituitary tumors
ES2665580T3 (es) 2011-11-11 2018-04-26 Gilead Apollo, Llc Inhibidores de ACC y usos de los mismos
PT3111950T (pt) 2012-02-24 2021-10-19 Univ Chicago Métodos e composições relacionadas com antagonismo recetor de glucocorticoide e cancro da próstata
US20130225633A1 (en) 2012-02-27 2013-08-29 Corcept Therapeutics, Inc. Phenyl heterocycloalkyl glucocorticoid receptor modulators
HUE029038T2 (en) 2012-05-25 2017-01-30 Janssen Sciences Ireland Uc Uracil spirooxetan nucleosides
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US9452255B2 (en) 2014-07-21 2016-09-27 Medtronic Minimed, Inc. Smart connection interface
EP3006453A1 (en) 2014-10-08 2016-04-13 Cosmo Technologies Ltd. 17alpha-monoesters and 17alpha,21-diesters of cortexolone for use in the treatment of tumors
US10047157B2 (en) 2014-12-19 2018-08-14 Alder Biopharmaceuticals, Inc. Humanized anti-ACTH antibodies and use thereof
WO2016140867A1 (en) 2015-03-02 2016-09-09 Corcept Therapeutics, Inc. Use of glucocorticoid receptor antagonist and somatostatin analogues to treat acth-secreting tumors
WO2016141365A1 (en) 2015-03-05 2016-09-09 Abraxis Bioscience, Llc Method for treating cancer based on level of glucocorticoid receptor
US9598459B2 (en) 2015-08-03 2017-03-21 Pop Test Oncology Llc Pharmaceutical compositions and methods
KR20180052120A (ko) 2015-08-13 2018-05-17 코어셉트 쎄라퓨틱스, 잉크. Acth-의존성 쿠싱 증후군을 감별 진단하는 방법
US9943505B2 (en) 2016-09-09 2018-04-17 Corcept Therapeutics, Inc. Glucocorticoid receptor modulators to treat pancreatic cancer
PH12017000049A1 (en) 2017-02-20 2018-08-29 S Heilveil Peter Aerial cable spacer
SG11201908790PA (en) 2017-03-31 2019-10-30 Corcept Therapeutics Inc Glucocorticoid receptor modulators to treat cervical cancer
AU2019404026B2 (en) 2018-12-19 2023-06-08 Corcept Therapeutics Incorporated Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound
AU2020239920A1 (en) 2019-03-18 2021-11-04 Arnold L. Newman Method of improving insulin sensitivity
EP4103180A4 (en) 2020-02-10 2024-03-13 Corcept Therapeutics Incorporated METHOD FOR STIMULATING AN ANTI-TUMOR RESPONSE USING A SELECTIVE GLUCOCORTICOID RECEPTOR MODULATOR
WO2022134033A1 (en) 2020-12-25 2022-06-30 Corcept Therapeutics Incorporated Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
IL317734A (en) 2022-06-28 2025-02-01 Corcept Therapeutics Inc METHODS FOR PREPARING HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS
WO2024077169A1 (en) 2022-10-06 2024-04-11 Corcept Therapeutics Incorporated Formulations of glucocorticoid receptor modulators

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013177559A2 (en) * 2012-05-25 2013-11-28 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
WO2015077530A1 (en) * 2013-11-25 2015-05-28 Corcept Therapeutics, Inc. Octahydro fused azadecalin glucocorticoid receptor modulators
WO2017151613A1 (en) * 2016-03-01 2017-09-08 Corcept Therapeutics, Inc. The use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors
WO2020172501A1 (en) * 2019-02-22 2020-08-27 Corcept Therapeutics Incorporated Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HAZEL J. HUNT, JOSEPH K. BELANOFF, IAIN WALTERS, BENOIT GOURDET, JENNIFER THOMAS, NAOMI BARTON, JOHN UNITT, TIMOTHY PHILLIPS, DENI: "Identification of the Clinical Candidate ( R )-(1-(4-Fluorophenyl)-6-((1-methyl-1 H -pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-hexahydro-1 H -pyrazolo[3,4- g ]isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methanone (CORT125134): A Selective Glucocorticoid Receptor (GR) Antagonist", JOURNAL OF MEDICINAL CHEMISTRY, vol. 60, no. 8, 27 April 2017 (2017-04-27), US , pages 3405 - 3421, XP055404285, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.7b00162 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12152028B2 (en) 2020-12-25 2024-11-26 Corcept Therapeutics Incorporated Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
US12370188B2 (en) 2022-10-06 2025-07-29 Corcept Therapeutics Incorporated Formulations of dazucorilant, a glucocorticoid receptor modulator

Also Published As

Publication number Publication date
AU2021410756A1 (en) 2023-07-06
EP4267577A4 (en) 2024-11-27
WO2022140600A1 (en) 2022-06-30
JP2024501956A (ja) 2024-01-17
CN116867780A (zh) 2023-10-10
CA3202354A1 (en) 2022-06-30
US12152028B2 (en) 2024-11-26
AU2021410756A9 (en) 2024-09-12
MX2023007404A (es) 2023-08-21
US20220227753A1 (en) 2022-07-21
JP7720914B2 (ja) 2025-08-08
US20250145620A1 (en) 2025-05-08
KR20230124985A (ko) 2023-08-28
AU2025203341B2 (en) 2026-03-05
EP4267577A1 (en) 2023-11-01
IL304005A (en) 2023-08-01
AU2025203341A1 (en) 2025-05-29
AU2021410756B2 (en) 2025-02-13

Similar Documents

Publication Publication Date Title
US20250145620A1 (en) Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
AU2025267321B2 (en) Polymorphs of pyrimidine cyclohexyl glucocorticoid receptor modulators
EP2854814B1 (en) Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
US20230416250A1 (en) Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
JP5570536B2 (ja) 鉱質コルチコイド受容体アンタゴニストおよび使用方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20966598

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20966598

Country of ref document: EP

Kind code of ref document: A1